The Transcription
Infidelity Platform
Company

For Drug Discovery and Development

Genclis is a privately held biotechnology company, based in Nancy, France.

It focuses on alternate RNA derived therapeutics.

Genclis has developed a technology platform based on its discovery of Transcription Infidelity (“TI”), causing gaps in mRNA. Proteins translated from these mRNA are designated TI proteins and hold specific immunological properties.

What is Transcription Infidelity?

Revolutionizing immunology one indication at a time.

Learn more about TI

Pipeline

Our current fields of drug development

Discovery

Preclinical

Phase I

Phase 2

Phase 3

Veterinary Allergy

Human Allergy

Severe Covid

Type I Diabetes

Lou Gehrig’s disease

  • 70% 70%
  • 30% 30%
  • 30% 30%
  • 10% 10%
  • 10% 10%
photo PDG Genclis

Word from our CEO

Welcome to Genclis!

I am proud to lead a team of highly skilled and enthusiastic scientists to tackle some of the most critical battles modern medicine faces.

Patients first

At Genclis, curing people is our main mission. My life’s goal has been to alleviate unnecessary suffering and pain. We have achieved major breakthroughs in the veterinary field and we are on the verge of victories for human medicine.

Driven by Science

Genclis employees all share a passion for science. Our job is to make sense of what has none.

This passion enabled us to discover a novel molecular biology mechanism, charter its rules, and find its role in the education of the immune system. Beyond immunology, our goal is to rule immunity. Our technology elicits, enhances, or tames antibodies.

Baby steps

Genclis explores unknown territories and de-risks its therapeutic solutions with convergent, highly robust preclinical data. As a small company with limited resources, we carefully arbitrage our many opportunities.

Company stewards

We are faithful stewards of the funds entrusted to us by our shareholders. Our financial statements reflect our stability. This unconventional biotech business model may be slow but it is steady.

Bernard Bihain, Co-founder and CEO

Bioinformatics

“We’re dedicated to improving patient outcomes with reliable AI-Powered technology and meaningful collaboration with biopharma, laboratories, and clinicians — aiming to provide patients with access to accurate diagnoses and effective treatments.”

Incorporation

Patents granted

Staff

PhDs / MDs

Publications

Publications

See more